The developed VPAC2-selective agonists are currently in the early stages of in vitro and in vivo studies, and the clinical specificity and efficacy still need further research; hence, it would be a while before viable applications of these agents could be implemented in type 2 diabetes treatment. The gene discussed is VIPR2; the disease is type 2 diabetes mellitus.